Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Pharma in Focus Jobs
White paper
Latest News
Companies respond on orphan reform
Consumers and pharmacos agree, the TGA's orphan drugs program is out-of-date and needs reform across the board.
Allergan/Teva deal low impact in Aust
Allergan's latest US$40.5 billion deal to sell its generics business to Teva will likely have 'minimal impact' in Australia, the company says.
Policy failure holds back manufacturing: CSL
Australia has many things right to undertake advanced manufacturing, says CSL's Gordon Naylor but government policy failures are letting us down.
AZ cancer drug deal includes Aust
AstraZeneca has sold rare cancer drug Caprelsa to Sanofi's Genzyme unit for up to US$300m in a deal that includes the Australian market.
Aust first trial for head & neck cancer drug
An Australian first head and neck cancer clinical trial has been launched to test the effectiveness of new drug, Nimoral.
Most Popular
Aust pharma facing 'second tier' status
Although Australia remains in the top 20 of the world's pharma markets, it could fall to 'second tier' status if industry turnover remains stagnant MA has warned.
Why cancer drugs are so costly
The 'unique characteristics' of the cancer drug market and emotions create a 'perfect storm' that drives up the prices for these drugs, say academics.
Roche prepares to sell Dee Why site
Roche is inviting 'expressions of interest' for its large local headquarters site at Dee Why NSW, due to changing business needs.
Another step forward for managed access
A new draft of the managed access framework has been released following its discussion at the March PBAC meeting, setting out criteria including using the scheme, price and patient agreement.
Mark Crotty leaves GMiA
Mark Crotty will step down as chairman of the GMiA today, after a two year stint. His replacement will be announced on 3 August, the GMiA said.
Pharma sales model needs disruption
'Pharma needs to disrupt the sales ecosystem' as technology changes the way that healthcare is provided and even consumed.
Pfizer improves meds app
Pfizer has launched an updated version of its patient support app, providing people with information on both their medication and medical condition.
Docs want more medication apps
Two in three Australian HCPs want pharma companies to develop apps to make medication guidelines easier to access, a new survey has revealed.
Health lists drop outs from PD calcs
The Department of Health has unveiled more than 300 originator brands it proposes to eliminate from price disclosure calculations and is calling for stakeholder reaction.
New biologics boost RA remission
Remission rates in rheumatoid arthritis have improved significantly since the introduction of biologic drugs, a new Australian study has found.
Hep C meds still 'out of reach': Hep Aust
As new hepatitis meds linger unlisted despite positive recommendations, Hepatitis Australia has used World Hepatitis Day today to step up its call for change.
Ads for OTC PPIs allowed from Oct
Esomeprazole will be the first S3 proton pump inhibitor for which advertising to consumers will be allowed, though it might be an indication of what is to come.
RA, hep C drugs drive AbbVie sales
AbbVie's global second quarter 2015 sales have risen 11.1% to US$5.475 billion, driven by flagship Humira and new hep C treatment Viekira.
NOACs increasing AF treatment
More patients with atrial fibrillation are being treated as a result of the availability NOACs, a new study has found, results that are matched by PBS data locally.
Pompe disease drug wins LSDP boost
After several submissions and rejections, Genzyme's Myozymewill finally list on the LSDP from September 1 for adult late onset Pompe disease.
Working Life
Public speaking, how to beat the fear
Public speaking has a bad reputation. The oft-quoted statistic is that around three-quarters of people fear it more than anything else but presentation skills are now considered vital to advancing your career, so overcoming the fear is key.
Approvals Action
First threat to $60m Velcade
Potential generic competition for Janssen's cancer treatment Velcade, worth close to $60 million a year in PBS earnings, has appeared on the drugs register.
Special Report
What next for regulation
The report into medicines regulation has been released, to a largely positive response, but with stakeholder forums taking place next week, industry is waiting to see what will be adopted.
Open Forum
Crestor case to set new threshold
When the High Court hands down its decision in the Crestor case, it is expected to clarify assessment of the obviousness of a method of treatment, write Rebecca Currey and Jane Owen of law firm Bird & Bird.
Pipeline Monitor
New drug class approvals come fast
Amgen scores first in new PCSK9 lipid lowerers, PD-1 inhibitor expands, plus BMS's new HIV combo.
FREE Content
Events & Conferences
Pharma in Focus Jobs
Ascott Sales
christian louboutin Sandals hermes replica belt prada online celine tote sale yves saint laurent discount prada replica bags hermes birkin replica hermes handbags birkin chloe online prada cheap christian louboutin pumps outlet hermes kelly replica chloe cheap chloe handbags replica hermes replica handbags chloe cheap prada cheap celine trapeze sale hermes kelly outlet yves saint laurent shoulder bags replica chloe bags christian louboutin Sandals replica chloe handbags online